Viagra Gervasi

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Viagra Gervasi

The product known commercially as Viagra Gervasi is defined by its active ingredient, Sildenafil, a prescription-only medicine classified as a Phosphodiesterase type 5 (PDE5) inhibitor. It is a synthetic organic compound utilized for its potent, selective effects on the body's vascular system.


Property Description
Active ingredient Sildenafil (as Sildenafil citrate)
Form Film-coated tablet, Oral suspension, Injectable solution
Pharmacological class Phosphodiesterase type 5 (PDE5) inhibitor
Origin Synthetic organic compound

What Type of Medicine is Viagra Gervasi?

Viagra Gervasi is fundamentally a PDE5 inhibitor, representing a therapeutic class that selectively modulates blood flow by targeting a specific enzyme in certain vascular beds. The medicine's identity is rooted in its active substance, Sildenafil, which is chemically synthesized and is not derived from natural sources. This precise chemical structure allows it to bind to the PDE5 enzyme, protecting the critical signaling molecule cyclic guanosine monophosphate (cGMP) from premature degradation. This selective action is clinically recognized for providing effective hemodynamic support.

Composition and Pharmaceutical Forms

The medicine is formulated as a single-active-ingredient product containing Sildenafil, typically as the citrate salt. It is made available in several dosage forms for systemic administration, which include the common oral film-coated tablet, an oral suspension, and an injectable solution for intravenous (IV) administration. These different preparations allow for varying routes of administration based on the patient's condition or clinical urgency.

General Therapeutic Purpose

The overarching purpose of Sildenafil is to leverage its physiological action to enhance blood flow by promoting vasodilation in target tissues where circulation may be restricted. The inhibition of the PDE5 enzyme allows a natural signaling molecule to accumulate, leading to the relaxation of vascular smooth muscle. This results in a controlled increase in localized blood flow, which is the fundamental benefit provided by this class of medicine, particularly useful in scenarios requiring improved circulatory dynamics.

Regulatory References

  1. Sildenafil Mechanism of Action (NIH)
Advertisements

What side effects are possible with Viagra Gervasi?

Possible side effects and safety information

Official regulatory documents classify the potential adverse effects of Sildenafil, the active ingredient in Viagra Gervasi, across specific frequency tiers and physiological systems. This information is derived from clinical trials and post-marketing surveillance.

Frequency-Based Adverse Reactions

Adverse reactions are formally grouped by how often they are expected to occur:

  • Very Common: Headache and Flushing (sensation of warmth or redness) are consistently documented.
  • Common: Side effects in this category include Dizziness, Dyspepsia (indigestion), Abnormal Vision (such as blurred vision or a color tinge), Nasal Congestion, Back Pain, and Myalgia (muscle pain).

Serious Adverse Reactions and Safety Constraints

Regulatory authorities highlight certain less common events due to their clinical significance:

  • Eye and Ear Effects: Cases of sudden decrease or loss of vision, potentially due to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), and sudden decrease or loss of hearing have been reported in temporal association with use.
  • Priapism: A prolonged erection lasting more than four hours is an explicitly documented, serious risk that requires immediate attention as defined by labeling.
  • Cardiovascular Events: Serious events, including myocardial infarction or stroke, have been reported post-marketing, often occurring during or shortly after sexual activity.

Population-Specific Safety Considerations

The official profile specifies precautions for certain patient populations:

  • Nitrate Use: There is an absolute regulatory restriction against use in patients concurrently taking any form of organic nitrates or guanylate cyclase stimulators due to the risk of severe, potentially life-threatening hypotension.
  • Hepatic/Renal Impairment: Sildenafil clearance is reduced in patients with severe renal impairment or hepatic cirrhosis, which may necessitate caution and is sometimes cited as a use restriction.
  • Pediatric PAH Use: For Pulmonary Arterial Hypertension in children, the chronic use of Sildenafil is generally not recommended by some regulators due to observations of increased mortality at higher doses in clinical trials.

This structured regulatory profile defines the known safety boundaries of the medicine, moving from common, expected effects to rare but critical safety constraints.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation indicates that an overdose of the active ingredient, Sildenafil, is primarily characterized by an increased incidence and severity of known adverse effects. Clinical manifestations seen with exposures significantly higher than the maximum recommended dose may include severe headache, pronounced flushing, dizziness, and hypotension (decreased blood pressure).

When a specific severe event occurs, the regulator mandates seeking immediate medical attention. This is required if an erection persists for longer than four hours (priapism), as untreated priapism carries the risk of penile tissue damage and permanent loss of potency. Immediate medical care must also be sought for sudden loss of vision or sudden decrease or loss of hearing.

Management and Clearance

Classification Official Regulatory Statement
Antidote Availability No specific antidote is known for Sildenafil overdose.
Supportive Measures Management is limited to symptomatic and standard supportive measures.
Clearance Hemodialysis is not expected to accelerate clearance due to high plasma protein binding.

Population-Specific Note: Sildenafil clearance is documented to be reduced in patients with severe renal or hepatic impairment, potentially leading to higher drug exposure and increased severity of dose-related effects in these populations.

Advertisements

Therapeutic Uses of Viagra Gervasi

The primary purpose of this medicine is commonly used to help with conditions presenting with systemic or localized discomfort, across two distinct therapeutic areas.

This medication plays a role in managing symptom clusters that may become disruptive, specifically addressing erectile dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). The overall benefit helps maintain a sense of stability when symptoms are more noticeable.


Managing Erection Difficulties (Erectile Dysfunction)

The medication is commonly used to help with ED in adult men, focusing on symptoms like the inability to attain or maintain sufficient penile firmness. This supportive use may be part of symptomatic management for men whose ED is linked to conditions presenting with systemic or localized discomfort. The goal is to contribute to improved comfort by supporting improved functional stability.


Improving Function in Pulmonary Arterial Hypertension (PAH)

A second important use is applied across domains where additional symptomatic support is needed for PAH in both adults and pediatric patient groups. It plays a role in managing the distressing symptoms associated with high pressure in the lung arteries, including shortness of breath and fatigue. The primary benefit may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Supports patients during difficult episodes This medicine contributes to easing the overall symptom load and supports general well-being during symptomatic phases across both therapeutic domains.

Regulatory References

  1. NIH MedlinePlus overview of Sildenafil
Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Sildenafil (Viagra Gervasi) is defined by official regulatory documentation that dictates who is permitted to use the medicine and who is absolutely excluded.


Populations for whom use is contraindicated

Sildenafil is strictly contraindicated for patients using any form of organic nitrates or soluble guanylate cyclase (sGC) stimulators. The medicine is also prohibited in cases of known hypersensitivity, a history of non-arteritic anterior ischaemic optic neuropathy (NAION), or severe pre-existing clinical conditions, including severe hypotension (BP <90/50 mmHg), severe hepatic impairment (Child-Pugh Class C), or a recent stroke or myocardial infarction.


Age and Condition-Specific Eligibility Rules

For the Erectile Dysfunction indication, Sildenafil is only permitted for adult men and is not indicated below age 18. For Pulmonary Arterial Hypertension (PAH), use is approved for children aged 1 year to 17 years. Patients with severe renal impairment or mild-to-moderate hepatic impairment require a lower starting dose to be considered due to reduced drug clearance. Use is not recommended in conditions like Pulmonary Veno-Occlusive Disease (PVOD) or hereditary degenerative retinal disorders. The use of Sildenafil in pregnancy and lactation is not established by adequate studies.

Advertisements

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Viagra Gervasi

Interaction Scope

Medicinal product categories with documented interactions include Organic Nitrates, Guanylate Cyclase Stimulators, and strong CYP3A4 inhibitors. The mechanistic basis is defined by two primary domains. Pharmacodynamic reinforcement leads to additive blood pressure lowering when co-administered with other vasodilators, such as Alpha-blockers. Pharmacokinetic interactions occur because clearance is primarily reduced by inhibition of the Cytochrome P450 enzymes CYP3A4 and CYP2C9.

Interaction Classifications (High-Level)

Interaction severity classification officially defines co-administration with any Organic Nitrate or Riociguat as formally contraindicated. The regulatory basis mandates specific procedural constraints to manage risk. This includes a maximum single dose of 25 mg in a 48-hour period when co-administered with Ritonavir, and the requirement that patients be stable on alpha-blocker therapy before initiating Sildenafil. Interaction relevance is also noted for specific populations; in patients with severe renal or hepatic impairment, reduced clearance leads to increased exposure and requires careful management.

Resulting Interaction Structure

Official interaction statements define a strict profile: strong enzyme inhibitors significantly increase drug exposure, while co-administration with a high-fat meal reduces the rate of absorption. These regulatory constraints are focused on preventing clinically significant hypotension and managing overall systemic exposure.

Advertisements

Mechanism of Action

Inhibition of the Phosphodiesterase Type 5 (PDE5) Enzyme

The mechanism of Viagra Gervasi relies on the selective competitive inhibition of the PDE5 enzyme, a molecular target found primarily in vascular smooth muscle cells. By blocking this enzyme, the active ingredient, Sildenafil, prevents the breakdown of the essential signaling molecule cGMP (cyclic guanosine monophosphate), leading to its increased concentration within the cell.

Amplification of the Nitric Oxide-cGMP Pathway

Sildenafil acts as an amplifier within the Nitric Oxide (NO)-cGMP signaling pathway, which regulates vascular tone. The sustained elevation of cGMP triggers a cascade that lowers intracellular calcium levels, causing the vascular smooth muscle to relax and resulting in vasodilation (vessel widening). This action results directly in localized increases in blood flow.

Mechanism Constraint and Dependence on Stimulation

A key feature of the mechanism is its dependence on physiological stimulation, as the mechanism requires the presence of Nitric Oxide (NO) being released by the body. This constraint ensures the resulting vasodilation and blood flow changes are targeted and context-dependent. The pharmacological effect remains contingent upon the activation of the endogenous NO pathway.

Advertisements

Dosage and Administration Information

How to Use Viagra Gervasi (Sildenafil): Official Administration Guidelines

Viagra Gervasi, whose active ingredient is Sildenafil, is administered following strict regulatory protocols that differentiate its use for Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). All usage instructions regarding dose, route, and frequency are mandated by official governmental health agencies.


Approved Administration Routes and Forms

Sildenafil is officially approved for oral administration as a film-coated tablet or oral suspension, and for intravenous (IV) injection when managing PAH in patients temporarily unable to take the oral form.


Labeled Dosing Regimens and Frequency

Condition Starting Dose Maximum Dose/Frequency Administration Schedule
Erectile Dysfunction (ED) 50 mg as needed 100 mg (once per day maximum) Taken approximately 1 hour before activity
Pulmonary Arterial Hypertension (PAH) 20 mg (Oral) or 10 mg (IV) 80 mg (Oral, three times a day) Fixed schedule, three times a day (TID)

Administration Conditions and Adjustments

Oral tablets may be taken with or without food; however, a heavy, high-fat meal may delay the onset of action.

Population-Specific Dosing: Official guidelines recommend considering a lower starting dose of 25 mg for ED in specific populations, including older adults (ge 65 years) and those with severe renal or hepatic impairment. For PAH, dosing is weight-based for pediatric patients (ge 1 year of age).

Special Instructions: The oral suspension requires reconstitution with water and must be shaken well prior to administration. For PAH, the IV injection is used for temporary continued treatment and administered as a bolus injection.

These official administration instructions ensure that Sildenafil is used according to the precise standards established by regulatory bodies, defining the mandatory dose, route, and schedule for each approved condition.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence: Sildenafil Citrate

The efficacy and safety of sildenafil citrate (the active component in Viagra Gervasi) have been investigated in numerous large-scale, randomized, double-blind, placebo-controlled clinical trials, primarily for treating erectile dysfunction (ED) across a broad patient population.


Efficacy Results

Clinical studies have consistently evaluated the drug's effect on the ability to achieve and maintain an erection sufficient for sexual intercourse. Key findings from pooled data and meta-analyses include:

  • Success Rates: In trials, men receiving sildenafil reported a statistically significant greater proportion of successful attempts at intercourse compared to those receiving placebo.
  • Patient Response: A high percentage of patients across various studies reported an improvement in their erections when compared to baseline.
  • Subgroups: Efficacy was also evaluated and observed in subgroups considered more difficult to treat, such as those with ED related to diabetes mellitus or following radical prostatectomy.
Dose (mg) Percentage Reporting Global Improvement (Approximate Range)
25 62%
50 74%
100 82%

Safety and Tolerability

The safety profile of sildenafil has been studied in both short-term and long-term (up to 4 years) open-label extension studies. Common adverse events reported in clinical trials include headache, flushing, and dyspepsia (indigestion).

Research has also specifically addressed the drug’s use in patients with underlying health conditions, noting that sildenafil is generally not recommended for use with concurrent nitrate medications due to the potential for a severe drop in blood pressure.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Viagra Gervasi (FAQ)

Q: How quickly does Viagra Gervasi start to work?

A: Official pharmacological data indicates that the active ingredient reaches its highest concentration in the bloodstream between 30 and 120 minutes after taking the oral tablet on an empty stomach. This time frame is important for understanding the typical onset of the medicine's activity.

Q: How long does the effect of Viagra Gervasi last?

A: The duration of the medicine's presence in the body is often described by its half-life, which is approximately 3 to 5 hours. This means it takes this long for the concentration of the active ingredient in the bloodstream to decrease by half.

Q: Are there any specific foods that should be avoided when taking Viagra Gervasi?

A: Regulatory information states that taking the medicine with a heavy, high-fat meal may slow down the rate at which the body absorbs the active ingredient. While no specific foods are forbidden, patients should be aware that a fatty meal could delay when the medicine begins to work.

Q: Does alcohol affect how Viagra Gervasi works?

A: Studies have examined the combination of the medicine with alcohol and found no significant impact on the concentration of the active ingredient in the body. However, alcohol is known to cause effects such as lowering blood pressure, which may overlap with the effects of this medicine.

Q: Is there any research on long-term use of Viagra Gervasi?

A: Yes, official clinical programs have included studies, such as open-label extension studies, that have examined the safety profile of the medicine during prolonged use. These programs have gathered data on the medicine’s long-term use for periods extending up to four years.

Q: Is it okay to take Viagra Gervasi every day?

A: The acceptable frequency of use depends on the condition being treated. For the Erectile Dysfunction indication, the labeling describes the dosage as being no more than once per day. Conversely, when used for Pulmonary Arterial Hypertension, the medicine is typically administered on a fixed schedule multiple times throughout the day.

Q: Is there a generic version of Viagra Gervasi available?

A: Yes, the active ingredient in Viagra Gervasi is Sildenafil, and following the expiration of relevant patents, generic versions of this medicine are now available from various manufacturers.

Q: What are the rules about using Viagra Gervasi and driving?

A: Official warnings indicate that the medicine may cause adverse effects like dizziness or changes to vision. Regulatory guidelines specify that patients should be aware of how they respond to the medicine before engaging in activities that require alertness, such as driving or operating heavy machinery.

Q: Is Viagra Gervasi ever prescribed for conditions other than its primary use?

A: Official regulatory documentation explicitly approves the medicine for two main indications: the treatment of Erectile Dysfunction and the treatment of Pulmonary Arterial Hypertension.

Q: What is the maximum number of times Viagra Gervasi can be used in a week?

A: The official labeled frequency for the Erectile Dysfunction indication is a maximum of once per day. Therefore, official guidance specifies that the medicine is not to exceed seven uses within a seven-day period.

Q: Is Viagra Gervasi sold over-the-counter anywhere?

A: The original formulation of the medicine is generally prescription-only. However, some health regulatory bodies have allowed certain alternative strengths or formulations of the active ingredient, Sildenafil, to be reclassified and made available without a prescription for specific uses.

Q: Can women use Viagra Gervasi?

A: The use of the medicine depends on the condition. For Erectile Dysfunction, it is approved for adult men. For the Pulmonary Arterial Hypertension indication, the medicine is approved for use in both men and women.

Q: Is Viagra Gervasi meant only for older people?

A: Official documents approve the medicine for use in adult men across all age groups for the Erectile Dysfunction indication. While a lower starting dose is sometimes considered for older adults, the medicine is not intended exclusively for this population. Furthermore, it is also approved for children in the Pulmonary Arterial Hypertension indication.

Q: Does Viagra Gervasi have a potential for misuse or dependence?

A: Official product labeling based on clinical data indicates that the medicine has not shown evidence of promoting tolerance, drug abuse potential, or physical dependence in patients.

Q: Does Viagra Gervasi cause any change in vision?

A: Yes, regulatory information lists vision changes as a possible side effect. Common effects include abnormal vision, which may involve a color tinge. Less common, but serious, reports include sudden decrease or loss of vision, potentially linked to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).

Q: Can Viagra Gervasi be taken with antacids?

A: Clinical studies have examined taking the medicine with certain antacids, specifically those containing magnesium hydroxide and aluminum hydroxide. The studies concluded that this combination does not cause a clinically significant change in how the active ingredient is absorbed by the body.

Q: What should a patient tell their doctor before starting Viagra Gervasi?

A: Official warnings specify conditions that a patient is required to disclose to their healthcare provider. This includes known heart problems, any history of eye disorders like Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), certain bleeding disorders, and especially the use of any form of nitrate-containing medicines.

Q: Can people with kidney disease be prescribed Viagra Gervasi?

A: The medicine can be used by patients with mild to moderate kidney impairment. Official guidelines state that a lower starting dose is typically considered for individuals with severe kidney impairment due to the potential for reduced clearance of the medicine from the bloodstream.

Q: Is it important to monitor anything specific while taking Viagra Gervasi?

A: Regulatory guidance indicates that patients with certain pre-existing conditions may require monitoring when starting the medicine. This is particularly relevant for those with specific cardiovascular risk factors or those who are also initiating treatment with alpha-blocker medicines.

Q: What are the reasons that Viagra Gervasi might not be suitable for someone?

A: The medicine has specific conditions for which its use is strictly prohibited, known as contraindications. This includes taking any form of nitrate medicines or guanylate cyclase stimulators, having severe low blood pressure, or experiencing a recent heart attack or stroke.

Q: Can Viagra Gervasi be used by people with diabetes?

A: Clinical studies conducted for the Erectile Dysfunction indication included a subgroup of patients with diabetes mellitus. The results from these trials demonstrated efficacy in this specific patient group.

Q: Is there a recommended time frame for use of Viagra Gervasi after eating?

A: For the Erectile Dysfunction indication, official labeling describes the medicine as being taken as needed approximately one hour before activity. While it can be taken with or without food, regulatory documents note that a heavy meal may delay the effects.

Q: Does Viagra Gervasi affect fertility or sperm count?

A: Based on preclinical safety data, studies conducted using the active ingredient did not show any adverse effects on the mobility or physical form of sperm when administered at the recommended dose levels.

Q: Is Viagra Gervasi linked to any changes in hearing?

A: Post-marketing surveillance has included reports of a sudden decrease or loss of hearing occurring in close time proximity to the use of the medicine. This event is highlighted in the official safety information.

Q: Does Viagra Gervasi have any known allergic reactions?

A: Yes, regulatory documents state that the medicine is contraindicated for use in any individual with known hypersensitivity (an allergic reaction) to the active ingredient, Sildenafil, or to any of the other non-active ingredients in the product formulation.

Q: How is the safety profile of Viagra Gervasi described in medical literature?

A: The official safety profile is structured by classifying expected adverse reactions according to how often they occur, such as 'Very Common' or 'Common.' It also includes listings of rare but clinically significant adverse events that have been identified in controlled studies and through post-marketing surveillance.

Advertisements

How should Viagra Gervasi be stored and disposed of?

Official Storage and Disposal Requirements for Viagra (Sildenafil)

Official regulatory guidance mandates specific storage and disposal practices to maintain the stability and safety of Sildenafil tablets.

Storage Conditions

Requirement Official Statement
Temperature Store at 25 C (77 F); permitted to range from 15 C to 30 C.
Protection Keep in the original container, tightly closed, and out of reach of children.

Disposal Instructions

Unused or expired Sildenafil should be managed through an official drug take-back program when available. If a take-back program is not accessible, the product must be mixed with an undesirable substance (such as dirt or used coffee grounds) in a sealed bag or container and discarded in the household trash. Do not flush Sildenafil tablets down the toilet or pour into any drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Viagra Gervasi found in:

A-Z Index: